COVID-19 Vaccination of Immunodeficient Persons (COVAXID) (COVAXID)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04780659|
Recruitment Status : Active, not recruiting
First Posted : March 3, 2021
Last Update Posted : September 9, 2021
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Covid19||Biological: Comirnaty (COVID-19, mRNA vaccine)||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||540 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Immunological Responses After Vaccination for COVID-19 With the Messenger Ribonucleic Acid (mRNA) Vaccine Comirnaty in Immunosuppressed and Immunocompetent Individuals. An Open and Non-randomized, Phase IV Multicenter Study|
|Actual Study Start Date :||February 23, 2021|
|Estimated Primary Completion Date :||December 31, 2022|
|Estimated Study Completion Date :||December 31, 2022|
Experimental: Vaccination with Comirnaty according to standard of care treatment
All study participants will receive Comirnaty according to current approval.
Biological: Comirnaty (COVID-19, mRNA vaccine)
Comirnaty will be administered two times, one at Day 0 and the second dose at Day 21.
- Assessment of seroconversion, defined as development of immunoglobulin G (IgG) antibodies against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) after vaccination of 2 doses in seronegative individuals. [ Time Frame: 2 weeks after second dose of vaccine. ]Proportion (95% confidence interval, CI) seroconverting to positive response to SARS-CoV-2 IgG serology test after two doses of vaccine, measured 2 weeks after second dose of vaccine.
- Assessment of any Adverse Events (AE) of the given vaccine [Safety and tolerability]. [ Time Frame: Duration of 0-14 days after each given vaccine dose. ]Proportion (95% CI) of study objects experiencing AE including reactogenicity, Serious Adverse Events (SAE), and Suspected Unexpected Serious Adverse Reaction (SUSAR).
- Frequency of SARS-CoV-2 infection documented by positive polymerase chain reaction (PCR) test. [ Time Frame: Day 0 - 6 months. ]Proportion (95% CI) of study objects with SARS-CoV-2 infection.
- Assessment of humoral and cellular immune responses in blood and saliva. [ Time Frame: Day 0- 6 months. ]Description of humoral and cellular immune responses in blood and saliva at baseline, and at time points day 0 (first vaccine dose), day 10 after first dose, day 21 (second vaccine dose), and 2 weeks, 3 months and 6 months after the second vaccine dose.
- Assessment of escape mutations of sequencing SARS-CoV-2 at breakthrough infection. [ Time Frame: Day 0-6 months. ]Genomic sequencing of SARS-CoV-2 at breakthrough infection.
- Assessment of graft versus host disease in allogenic stem cell transplanted persons after given vaccine. [ Time Frame: Day 0-6 months. ]Number of occurrence or worsening of graft versus host disease in allogenic stem cell transplanted persons after given vaccine will be described.
- Assessment of biopsy verified rejection in solid organ transplanted persons after given vaccine. [ Time Frame: Day 0-6 months. ]Number of occurrence of biopsy verified rejection in solid organ transplanted persons after given vaccine.
- Assessment of viremia, defined as HIV ribonucleic acid (RNA) > 50 copies/milliliter after vaccination in HIV infected persons. [ Time Frame: Day 0-6 months. ]Number of HIV infected persons with HIV ribonucleic acid (RNA) > 50 copies/milliliter after vaccination.
- Assessment of HIV deoxyribonucleic acid (DNA) levels after given vaccine in HIV infected persons. [ Time Frame: Day 0-6 months. ]HIV DNA levels at baseline, and 3 and 6 months after second dose of vaccine.
- Assessment of oral and gut microbiota in immunosuppressed and controls, in relation to immune response to vaccination. [ Time Frame: Day 0-6 months. ]Description of oral and fecal microbiota at baseline and association to immune responses.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
1. Individuals ≥18 years old
2a. In the opinion of the investigator, individuals with immunosuppressive disease who meet one of the following criteria:
- Primary immunodeficiency
- Human immunodeficiency virus (HIV)-infection
- Allogeneic stem cell transplantation / Chimeric antigen receptor (CAR T cell) therapy
- Solid organ transplant
- Chronic lymphatic leukemia
2b. In the opinion of the investigator, individuals without immunosuppressive disease or treatment without significant co-morbidity
3. Provision of signed informed consent to participate in the study
- Previous or ongoing Coronavirus Disease-19 (COVID-19).
- Coagulation disorders, other conditions associated with prolonged bleeding time or anticoagulant treatments, which according to the investigator contraindicate intramuscular injection. Conditions which can be corrected with measures such as platelet concentrate treatments, coagulation factors or other measures for people responsible for anticoagulants are not exclusion criteria.
- Planned to receive another vaccine within 14 days before the first dose of the study vaccine, or during the period from the first dose of the study vaccine up to 14 days after the second dose of the study vaccine, and vaccination with another vaccine which in the investigator's opinion cannot be planned outside these time periods
- Pregnancy or breast feeding.
- Hypersensitivity to the active substance or to any of the excipients contained in the vaccine
- Individuals who cannot understand the informed consent.
- Individuals who for other reasons are considered by investigators as not suitable for inclusion
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04780659
|Karolinska University Hospital|
|Stockholm, Huddinge, Sweden, 14186|
|Principal Investigator:||Soo Aleman, MD, PhD||Karolinska University Hospital, ME Infectious Diseases|
|Responsible Party:||Soo Aleman, MD, PhD, Karolinska Institutet|
|Other Study ID Numbers:||
|First Posted:||March 3, 2021 Key Record Dates|
|Last Update Posted:||September 9, 2021|
|Last Verified:||September 2021|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
|Plan Description:||Will submit data to European Union Drug Regulating Authorities Clinical Trials Database (EudraCT) and share data result. Will share research results and data through national COVID-19 data portal, operated by SciLifeLab Data Centre, Sweden.|
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
|Time Frame:||Within one year after study end.|
|Access Criteria:||Published in EudraCT and national COVID-19 data portal (SciLifeLab Data Centre)|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||No|
Respiratory Tract Infections
RNA Virus Infections
Respiratory Tract Diseases
Physiological Effects of Drugs